Electromed Q3 EPS $0.17 Beats $0.13 Estimate, Sales $13.87M Beat $13.80M Estimate

5/7/24 5:19:30 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $ELMD alert in real time by email

Electromed (AMEX:ELMD) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.13 by 30.77 percent. This is a 41.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $13.87 million which beat the analyst consensus estimate of $13.80 million by 0.51 percent. This is a 14.94 percent increase over sales of $12.07 million the same period last year.

Get the next $ELMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELMD

Date	Price Target	Rating	Analyst

More analyst ratings

$ELMD
Press Releases

Fastest customizable press release news feed in the world

Electromed, Inc. Schedules its First Quarter Fiscal 2025 Financial Results Conference Call for November 12, 2024 at 5:00 p.m. ET
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will release its financial results for the fiscal 2025 first quarter ended September 30, 2024, on November 12, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=
10/29/24 8:30:00 AM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing
Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing
10/28/24 8:30:00 AM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Electromed, Inc. Announces Share Repurchase Authorization
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that effective as of September 11, 2024, its board of directors authorized the repurchase of up to $5.0 million of Electromed common stock. The new authorization follows the exhaustion of Electromed's previous share repurchase authorization in the fourth quarter of fiscal 2024, as previously reported. The timing and amount of share repurchases pursuant to the authorization, if any, will be determined by management based on market conditions and other considerations. Repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiate
9/11/24 9:00:00 AM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$ELMD
Leadership Updates

Live Leadership Updates

Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing
Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing
10/28/24 8:30:00 AM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Electromed Names Jim Cunniff as President and Chief Executive Officer
Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle
6/5/23 8:15:00 AM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Electromed, Inc. Appoints Brad Nagel as Chief Financial Officer
Accomplished medical device leader to fill key strategic role Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has appointed Brad Nagel as the Company's Chief Financial Officer, effective November 14, 2022. Mr. Nagel brings to Electromed over fifteen years of financial leadership and strategic planning experience with Fortune 500 companies. Most recently, Mr. Nagel held the position of Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic and was a key contributor in driving the unit's revenue growth. In that role, he served as the primary busine
10/24/22 9:00:00 AM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Electromed, Inc. Schedules its First Quarter Fiscal 2025 Financial Results Conference Call for November 12, 2024 at 5:00 p.m. ET
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will release its financial results for the fiscal 2025 first quarter ended September 30, 2024, on November 12, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=
10/29/24 8:30:00 AM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Electromed, Inc. Announces Record Fiscal Year 2024 Financial Results
Record Q4 and full year financial results Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2024") and full year ("FY 2024") ended June 30, 2024. Q4 FY 2024 Financial Highlights Net revenues increased 9.0% to a record $14.8 million in Q4 FY 2024, from $13.6 million in the fourth quarter of the prior fiscal year. Gross margin was 76.2% of revenue, compared to 76.8% in the fourth quarter of the prior fiscal year. Operating income increased by 56.3% to a record $2.3 million or 15.7% of revenue, compared with $1.5 million or 11.0% of revenue in the fourth quarter of the p
8/27/24 4:20:00 PM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Electromed, Inc. Schedules its Fourth Quarter Fiscal 2024 Financial Results Conference Call for August 27, 2024 at 5:00 p.m. ET
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 fourth quarter ended June 30, 2024, on August 27, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 Fiscal 2024 Webcast F
8/14/24 4:05:00 PM ET
$ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Electromed Q3 EPS $0.17 Beats $0.13 Estimate, Sales $13.87M Beat $13.80M Estimate

Chat with this insight

Recent Analyst Ratings for $ELMD

$ELMD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CEO and President Cunniff James L. converted options into 87,500 shares and covered exercise/tax liability with 34,426 shares, increasing direct ownership by 205% to 78,974 units (SEC Form 4)

CEO and President Cunniff James L. was granted 15,900 shares, increasing direct ownership by 159% to 25,900 units (SEC Form 4)

Chief Financial Officer Nagel Bradley M. was granted 5,500 shares, increasing direct ownership by 47% to 17,100 units (SEC Form 4)

$ELMD Press Releases

Fastest customizable press release news feed in the world

Electromed, Inc. Schedules its First Quarter Fiscal 2025 Financial Results Conference Call for November 12, 2024 at 5:00 p.m. ET

Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

Electromed, Inc. Announces Share Repurchase Authorization

$ELMD Leadership Updates

Live Leadership Updates

Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

Electromed Names Jim Cunniff as President and Chief Executive Officer

Electromed, Inc. Appoints Brad Nagel as Chief Financial Officer

$ELMD Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Electromed Inc. (Amendment)

SEC Form SC 13G/A filed by Electromed Inc. (Amendment)

SEC Form SC 13D/A filed by Electromed Inc. (Amendment)

$ELMD Market Insights

Live Market Insights